Login
$CERO
$0.10 +$0.00 (0.0%) Close

Ownership

13F as of Q2 2026 · 71.6M shares outstanding

Who owns CERO?

By type of holder
Institutions 0.0% Insiders 58.5% Everyone else 41.5%
Concentration Top 4 holders own 13.0%
Ehrlich Christopher B 9.5% · Phoenix Biotech Sponsor, LLC 1.4%
Institutional ownership
0.0%
0.0 pts vs last qtr
Institutional holders
0
0 vs last qtr
Net shares bought
0
by institutions in Q2 2026
New / sold out
0 / 0
positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

None.

Biggest sellers in Q2 2026

None.

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for CERO THERAPEUTICS HOLDINGS, INC. in the last 12 months.

Is your stake being diluted?

There are not yet two fiscal years of reported share counts for CERO THERAPEUTICS HOLDINGS, INC..

How patient are the owners?

No 13F manager reports holding CERO.

Super Investors

Investment managers reporting CERO on Form 13F
No 13F manager reports holding CERO yet.

Institutional Funds

Mutual funds and ETFs reporting CERO on Form N-PORT; together they hold 0.0% of the company
FE
Fidelity Concord Street Trust
Position value
$14K
% of company
0.00%
% of the fund
0.00%
As of
August 31, 2025
FS
Fidelity Concord Street Trust
Position value
$1.21K
% of company
0.00%
% of the fund
0.00%
As of
August 31, 2025

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G
EC
Ehrlich Christopher B
Insider
Shares
6.8M
% of company
9.49%
Change vs last qtr
—
Held since
—
PB
Phoenix Biotech Sponsor, LLC
Insider
Shares
1.0M
% of company
1.40%
Change vs last qtr
—
Held since
—

2 more holders behind a free account

See every insider and 5%+ holder of CERO THERAPEUTICS HOLDINGS, INC..

Sign up free

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support